Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives

30 Apr 2025

Abstract excerpt

High-Grade Serous Ovarian Carcinoma (HGSOC) represents the most prevalent and lethal subtype of ovarian cancer, with approximately 225,000 new cases reported globally each year and a five-year survival rate of merely 49.1%. The clinical management of HGSOC encounters substantial challenges, primarily attributable to its intricate drug resistance mechanisms, which involve multiple biological processes, including...

Topics

Join the communities discussing this publication.

Cancer Mechanisms and Therapy
Ferroptosis and cancer prognosis
Ovarian cancer diagnosis and treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40370464
DOI: 10.3389/fimmu.2025.1556377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesPMID 40370464Read ↗

Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.Semantic proximity Read ↗

Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment OptionsSemantic proximity Read ↗

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.Semantic proximity Read ↗

Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene TargetsSemantic proximity Read ↗

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.Semantic proximity Read ↗

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read ↗

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.Semantic proximity Read ↗

Integrated analysis of scRNA-seq and bulk RNA-seq identifies FBXO2 as a candidate biomarker associated with chemoresistance in HGSOCSemantic proximity Read ↗

Does neoadjuvant chemotherapy bias the transcriptomic profile of platinum-sensitive advanced high grade serous ovarian cancer patients towards a resistant phenotype? Findings from a gene expression meta-analysisSemantic proximity Read ↗

Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary ReviewSemantic proximity Read ↗

The Changing View of High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.